Lestaurtinib

Search with Google Search with Bing

Information
Drug Name
Lestaurtinib
Description
Entry(CIViC)
2
CIViC
Disease Mutation EL ET ED CS VO TR Pubmed Links
lung adenocarcinoma NTRK1 NTRK1 FUSIONS NTRK1 NTRK1 FUSIONS D Predictive Supports Sensitivity/Response Somatic 3 24162815 Detail
acute myeloid leukemia FLT3 ITD FLT3 ITD B Predictive Supports Sensitivity/Response Somatic 4 14726387 Detail
Annotation
Description Associated Genes Associated Variants Sensitivity Supported Source Links
Two patients were found to harbor gene fusions mai... NTRK1 NTRK1 NTRK1 FUSIONS NTRK1 NTRK1 FUSIONS Sensitivity true CIViC Evidence detail
CEP701 was effective in reducing blast counts of 5... FLT3 FLT3 ITD FLT3 ITD Sensitivity true CIViC Evidence detail
NCT ID Status Phase Summary Start date Completion date
NCT00557193 Active, not recruiting Phase 3 Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia January 15, 2008 June 28, 2024
NCT00084422 Completed Phase 1 N2001-03: CEP-701 in Treating Young Patients With Recurrent or Refractory High-Risk Neuroblastoma August 2003 February 2011
NCT00469859 Completed Phase 1/Phase 2 Lestaurtinib, Cytarabine, and Idarubicin in Treating Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia June 2007 March 2010
NCT00586651 Completed Phase 2 Open-Label Study of Oral CEP-701 (Lestaurtinib) in Patients With Polycythemia Vera or Essential Thrombocytosis December 2007 September 2010